The Zacks Analyst Blog Highlights: Royal Dutch Shell, Kinder Morgan, El Paso Pipeline Partners, Total SA and Omnicell

 The Zacks Analyst Blog Highlights: Royal Dutch Shell, Kinder Morgan, El Paso
                   Pipeline Partners, Total SA and Omnicell

PR Newswire

CHICAGO, Jan. 30, 2013

CHICAGO, Jan. 30, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Royal Dutch Shell plc
(NYSE:RDS.A), Kinder Morgan Inc (NYSE:KMI), El Paso Pipeline Partners, L.P.
(NYSE:EPB), Total SA (NYSE:TOT) and Omnicell Inc. (Nasdaq:OMCL).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday's Analyst Blog:

Shell to Export LNG Jointly

Shell US Gas & Power LLC – a subsidiary of Royal Dutch Shell plc (NYSE:RDS.A)
– Southern Liquefaction Company, LLC – subsidiary of Kinder Morgan Inc
(NYSE:KMI) – and a unit of El Paso Pipeline Partners, L.P. (NYSE:EPB)
announced their plan to jointly form a limited liability company. The new
entity will develop an export-ready natural gas liquefaction plant at a
shipping terminal near Savannah, Georgia.

Upon corporate and regulatory approvals, the newly formed company will use El
Paso's existing pipeline and terminal infrastructure to modify its Elba
Express Pipeline and Elba Island LNG Terminal. The developed facility will
export liquefied natural gas (LNG) by ship. A small-scale liquefaction unit of
Shell will be included with the existing Elba Island facility to facilitate
speedy construction.

Per the deal, Kinder Morgan owned El Paso will have a 51% stake in the new
company and operate the facility. Shell will have the remaining 49% stake and
100% of the liquefaction capacity. It is estimated that the facility will have
a capacity of 2.5 million tons per year upon completion.

The Free Trade Agreement approval has been sanctioned to the project and the
non-Free Trade Agreement approval is also expected soon. Management at Shell
believes that this deal will meet the world's growing energy requirement and
boost the U.S. economy.

In terms of assets, Royal Dutch Shell owns a strong and diversified portfolio
of global energy businesses that offer attractive long-term growth
opportunities. The group's strong inventory of development projects and
increased capital expenditures should help volume growth in the long run.

However, Royal Dutch Shell conducts operations in many countries. As such, the
group is exposed to risks associated with doing business abroad. Such risks
include embargoes and/or expropriation of assets, exchange rate risks,
terrorism and political/civil sentiment.

Royal Dutch Shell currently carries a Zacks Rank #3 (Hold), implying that it
is expected to perform in line with the broader U.S. equity market over the
next one to three months. Another oil company Total SA (NYSE:TOT) having a
Zacks Rank #2 (Buy) is also expected to perform in line with the market.

Omnicell Gains Foothold in Qatar

Omnicell Inc. (Nasdaq:OMCL), provider of end-to-end automation solutions for
medication-use process, continues to expand its client base. The company along
with its partner Mannai Corporation has been selected as the exclusive
provider of automated medication management solutions throughout the Sidra
Medical and Research Center in Doha, Qatar.

Sidra Medical and Research Center, which is currently under construction, will
be focusing on woman and child health on a regional and global basis. This
center will be a complete digital facility with 400 beds at the beginning with
an expansion plan of up to 550 beds at a later phase. To support its
all-digital facility, Sidra will deploy Omnicell's G4 platform.

The decentralized pharmacy model of the company's G4 platform is expected to
enhance nursing workflow and standards of patient care at Sidra. Considering
that the company's offerings were selected after a worldwide competitive
review of medication automation technology, selection of Omnicell implies a
clear competitive edge over other players.

In a concerted effort to offer unparalleled medical facilities, Sidra plans to
standardize its management solutions by implementing other offerings from
Omnicell to better manage its hospital. These include the Anesthesia
Workstation, the Savvy mobile medication workstation and the Anywhere RN
remote medication management system.

Our Take

Omnicell has already established its presence in the Middle East. Last year,
the company inked an agreement with King Faisal Specialist Hospital and
Research Center, Riyadh (accredited by The Joint Commission International) to
replace all of its operating systems with the company's Anesthesia
Workstations. The latest deal will expand Omnicell's foothold in the Middle
East market.

This is well-aligned with the company's long-running goal of driving growth
through expansion in international markets. Given that the overseas market is
less than 1% penetrated, increasing awareness of automation benefits and
higher investment in information technology by healthcare providers should
provide incremental revenue opportunities for Omnicell.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com